BNT162b2 COVID-19 疫苗的安全性和致反应性：开发、上市后监测和真实世界数据

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-02-26 DOI:10.1080/21645515.2024.2315659

Frank van den Ouweland, Nicola Charpentier, Özlem Türeci, Ruben Rizzi, Federico J. Mensa, Claudia Lindemann, Shanti Pather

引用次数: 0

摘要

严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引发的大流行促使创新者、疫苗开发商、监管机构和其他利益相关者采取紧急行动，以确保公众能够接种 SARS-CoV-2 疫苗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to urgent actions by innovators, vaccine developers, regulators, and other stakeholders to ensure public acce...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

自引率

8.30%

发文量

审稿时长

1 months

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.